Vanda Pharmaceuticals Inc. 8-K

What Happened
On March 10, 2026, Vanda Pharmaceuticals (VNDA) filed an 8-K under Item 7.01 disclosing that Mihael Polymeropoulos, M.D. (President, CEO and Chairman), appeared on Fox Business’ Mornings with Maria. He discussed Vanda’s pricing and commercial strategy for NEREUS™ — recently approved by the FDA for prevention of motion‑induced vomiting — and disclosed that the company is developing NEREUSRx™, a direct‑to‑consumer channel for access to NEREUS. Dr. Polymeropoulos indicated NEREUS will be available “in the next couple of months.”

Key Details

• Filing date / disclosure: March 10, 2026 (Item 7.01 Regulation FD Disclosure).
• Executive: Mihael Polymeropoulos, M.D., President, Chief Executive Officer and Chairman of the Board.
• Product: NEREUS™ — FDA approved for prevention of vomiting induced by motion.
• Commercial plan: Development of NEREUSRx™ direct‑to‑consumer access; product availability expected within the next couple of months.
• Source: Interview on Fox Business’ Mornings with Maria (video referenced in filing).

Why It Matters
This public disclosure gives investors the company’s near‑term commercialization timeline and channel strategy for NEREUS without providing financial details. The announcement signals progress toward market launch and a direct‑to‑consumer distribution approach that could affect how the product reaches patients and how revenue is recognized once sales begin. Investors should look for upcoming formal launch communications, pricing details, and sales guidance for material financial impact.